We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sen. Bernie Sanders (I-Vt.), chair of the Senate Committee on Health, Education, Labor and Pensions (HELP), along with Democrats on the committee, has launched an investigation into the high price of asthma inhalers in the U.S., targeting four makers of the devices — AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline (GSK) and Teva Pharmaceuticals. Read More
This edition of Quick Notes looks at recent FDA Class I and company recalls involving patient return electrodes, pump-incompatible syringes, unintentional double drug dosing and missing zeroes. Read More
Boston Scientific, GSK and Johnson & Johnson have each announced billion dollar acquisitions this week with major deals designed to expand the companies’ portfolios in very specific areas. Read More
The FDA launched a new search function on its website, designed to help users search for pharmaceutical quality-related guidances, compliance programs and manuals of policies and procedures (MAPP). Read More
The Orphan Drug Act yielded 491 approvals from 1990-2022 — and 73 of these drugs are among the top 200 most profitable in the world, with global sales exceeding $1 billion, a new analysis has determined. Read More
Suzhou Ribo Life Science and Ribocure Pharmaceuticals (Ribo) announced a $2 billion collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). Read More
The Biden Administration has signaled that it wants HHS to begin using the Defense Production Act (DPA) of 1950 to allow the government to invest in domestic manufacturing of essential medicines to shore up the drug supply chain. Read More
While the FDA has signaled concerns that drugs like Ozempic and Wegovy (semaglutide) come with an increased risk of suicidal ideation, a new study in the journal Nature says they don’t. Read More
How the FDA handles internal scientific disagreements and whether scientists have faced retaliation for expressing differing scientific views is the subject of a letter sent by the House Energy and Commerce Committee to the FDA. Read More